Literature DB >> 15339642

Clearance of Alzheimer's Abeta peptide: the many roads to perdition.

R E Tanzi1, R D Moir, S L Wagner.   

Abstract

The amyloid hypothesis of Alzheimer's disease (AD) maintains that the accumulation of the amyloid beta protein (Abeta) is a critical event in disease pathogenesis. A great deal of both academic and commercial research has focused on the mechanisms by which Abeta is generated. However, investigations into the mechanisms underlying Abeta clearance have blossomed over the last several years. This minireview will summarize pathways involved in the removal of cerebral Abeta, including enzymatic degradation and receptor-mediated efflux out of the brain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15339642     DOI: 10.1016/j.neuron.2004.08.024

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  163 in total

Review 1.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

2.  Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver.

Authors:  Neha Sehgal; Alok Gupta; Rupanagudi Khader Valli; Shanker Datt Joshi; Jessica T Mills; Edith Hamel; Pankaj Khanna; Subhash Chand Jain; Suman S Thakur; Vijayalakshmi Ravindranath
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

3.  Pulsations with reflected boundary waves: a hydrodynamic reverse transport mechanism for perivascular drainage in the brain.

Authors:  M Coloma; J D Schaffer; R O Carare; P R Chiarot; P Huang
Journal:  J Math Biol       Date:  2016-01-04       Impact factor: 2.259

4.  Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice.

Authors:  Huang Huang; Sipei Nie; Min Cao; Charles Marshall; Junying Gao; Na Xiao; Gang Hu; Ming Xiao
Journal:  Age (Dordr)       Date:  2016-07-21

5.  Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease.

Authors:  Martin J Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; Pankaj D Mehta; Frances Prelli; David Quartermain; Thomas Wisniewski
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

6.  Elevation in plasma Abeta42 in geriatric depression: a pilot study.

Authors:  Nunzio Pomara; P Murali Doraiswamy; Lisa M Willoughby; Amy E Roth; Benoit H Mulsant; John J Sidtis; Pankaj D Mehta; Charles F Reynolds; Bruce G Pollock
Journal:  Neurochem Res       Date:  2006-04-01       Impact factor: 3.996

Review 7.  The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases.

Authors:  S Park; K W Mathis; I K Lee
Journal:  Rev Endocr Metab Disord       Date:  2014-03       Impact factor: 6.514

8.  Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system.

Authors:  Robert D Bell; Abhay P Sagare; Alan E Friedman; Gurrinder S Bedi; David M Holtzman; Rashid Deane; Berislav V Zlokovic
Journal:  J Cereb Blood Flow Metab       Date:  2006-11-01       Impact factor: 6.200

9.  Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease.

Authors:  Binggui Sun; Yungui Zhou; Brian Halabisky; Iris Lo; Seo-Hyun Cho; Sarah Mueller-Steiner; Nino Devidze; Xin Wang; Anders Grubb; Li Gan
Journal:  Neuron       Date:  2008-10-23       Impact factor: 17.173

10.  Blocking the interaction between apolipoprotein E and Aβ reduces intraneuronal accumulation of Aβ and inhibits synaptic degeneration.

Authors:  Magdalena A Kuszczyk; Sandrine Sanchez; Joanna Pankiewicz; Jungsu Kim; Malgorzata Duszczyk; Maitea Guridi; Ayodeji A Asuni; Patrick M Sullivan; David M Holtzman; Martin J Sadowski
Journal:  Am J Pathol       Date:  2013-03-13       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.